Shuk-Mei Ho
Concepts (588)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phenols | 30 | 2025 | 92 | 7.660 |
Why?
| | Benzhydryl Compounds | 28 | 2021 | 69 | 6.570 |
Why?
| | Prostatic Neoplasms | 36 | 2022 | 400 | 5.590 |
Why?
| | Epigenesis, Genetic | 22 | 2025 | 407 | 4.490 |
Why?
| | DNA Methylation | 28 | 2025 | 592 | 4.450 |
Why?
| | Prostate | 24 | 2020 | 117 | 4.230 |
Why?
| | Estradiol | 21 | 2021 | 215 | 3.810 |
Why?
| | Endocrine Disruptors | 17 | 2025 | 32 | 3.530 |
Why?
| | Estrogen Receptor beta | 17 | 2019 | 54 | 3.020 |
Why?
| | Prenatal Exposure Delayed Effects | 11 | 2021 | 196 | 2.660 |
Why?
| | Gene Expression Regulation, Neoplastic | 20 | 2024 | 858 | 2.370 |
Why?
| | Environmental Exposure | 12 | 2024 | 216 | 2.360 |
Why?
| | Maternal Exposure | 6 | 2025 | 101 | 1.970 |
Why?
| | Asthma | 6 | 2018 | 316 | 1.730 |
Why?
| | CpG Islands | 10 | 2025 | 121 | 1.720 |
Why?
| | Estrogens | 13 | 2020 | 223 | 1.710 |
Why?
| | Environmental Pollutants | 7 | 2024 | 106 | 1.660 |
Why?
| | Testosterone | 8 | 2016 | 141 | 1.620 |
Why?
| | Air Pollutants | 6 | 2018 | 75 | 1.540 |
Why?
| | Air Pollutants, Occupational | 4 | 2020 | 14 | 1.510 |
Why?
| | Occupational Exposure | 4 | 2021 | 111 | 1.450 |
Why?
| | Pregnancy | 25 | 2025 | 2675 | 1.270 |
Why?
| | Spermatogenesis | 2 | 2021 | 13 | 1.270 |
Why?
| | Animals | 57 | 2024 | 13523 | 1.240 |
Why?
| | Promoter Regions, Genetic | 12 | 2019 | 474 | 1.220 |
Why?
| | Male | 73 | 2022 | 26696 | 1.220 |
Why?
| | Benzo(a)pyrene | 4 | 2018 | 13 | 1.190 |
Why?
| | Rats | 25 | 2021 | 3202 | 1.180 |
Why?
| | Diet, High-Fat | 4 | 2021 | 237 | 1.130 |
Why?
| | Humans | 93 | 2025 | 52336 | 1.080 |
Why?
| | Breast Neoplasms | 10 | 2016 | 1206 | 1.080 |
Why?
| | Cell Line, Tumor | 25 | 2024 | 1436 | 1.040 |
Why?
| | Gene Expression Profiling | 11 | 2015 | 1110 | 1.010 |
Why?
| | Receptors, Estrogen | 6 | 2019 | 132 | 0.990 |
Why?
| | Female | 56 | 2025 | 28105 | 0.980 |
Why?
| | Centrosome | 2 | 2016 | 11 | 0.980 |
Why?
| | Fetal Blood | 6 | 2025 | 79 | 0.980 |
Why?
| | Racemases and Epimerases | 3 | 2011 | 18 | 0.970 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2017 | 122 | 0.970 |
Why?
| | Diet | 4 | 2019 | 588 | 0.960 |
Why?
| | Veterans | 2 | 2021 | 581 | 0.910 |
Why?
| | Disease Susceptibility | 5 | 2012 | 96 | 0.900 |
Why?
| | Butter | 2 | 2021 | 4 | 0.880 |
Why?
| | Adenocarcinoma | 5 | 2015 | 405 | 0.870 |
Why?
| | Sex Characteristics | 4 | 2018 | 198 | 0.870 |
Why?
| | Rats, Sprague-Dawley | 15 | 2021 | 1552 | 0.840 |
Why?
| | Metallothionein | 2 | 2015 | 9 | 0.820 |
Why?
| | Cell Movement | 4 | 2014 | 277 | 0.800 |
Why?
| | Response Elements | 2 | 2013 | 29 | 0.780 |
Why?
| | Genetic Predisposition to Disease | 5 | 2015 | 528 | 0.770 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2024 | 85 | 0.770 |
Why?
| | Interferon-gamma | 2 | 2013 | 179 | 0.750 |
Why?
| | Infertility, Male | 1 | 2021 | 11 | 0.750 |
Why?
| | Estrogens, Non-Steroidal | 8 | 2015 | 15 | 0.740 |
Why?
| | Signal Transduction | 14 | 2020 | 1716 | 0.720 |
Why?
| | Cell Proliferation | 10 | 2017 | 1029 | 0.720 |
Why?
| | Dietary Fats | 1 | 2021 | 130 | 0.700 |
Why?
| | Toxicity Tests | 1 | 2020 | 57 | 0.690 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 10 | 2016 | 583 | 0.680 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2020 | 41 | 0.680 |
Why?
| | MicroRNAs | 5 | 2016 | 387 | 0.670 |
Why?
| | Sexual Maturation | 2 | 2018 | 19 | 0.650 |
Why?
| | Electronic Waste | 3 | 2018 | 3 | 0.650 |
Why?
| | Aging | 4 | 2017 | 708 | 0.630 |
Why?
| | Gene Regulatory Networks | 3 | 2017 | 111 | 0.620 |
Why?
| | Transcription, Genetic | 6 | 2013 | 385 | 0.620 |
Why?
| | Prostatic Intraepithelial Neoplasia | 4 | 2015 | 8 | 0.610 |
Why?
| | Epigenomics | 2 | 2016 | 75 | 0.600 |
Why?
| | Military Personnel | 1 | 2020 | 177 | 0.590 |
Why?
| | Stress, Psychological | 1 | 2020 | 273 | 0.590 |
Why?
| | Chromosomes, Human, X | 1 | 2018 | 18 | 0.590 |
Why?
| | Depressive Disorder | 1 | 2020 | 334 | 0.580 |
Why?
| | Anxiety | 1 | 2020 | 300 | 0.570 |
Why?
| | Reproduction | 2 | 2016 | 64 | 0.570 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2016 | 57 | 0.560 |
Why?
| | Embryonic Development | 2 | 2015 | 18 | 0.550 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 177 | 0.550 |
Why?
| | Microtubules | 2 | 2016 | 39 | 0.550 |
Why?
| | Transcriptome | 2 | 2021 | 367 | 0.540 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.540 |
Why?
| | Gene-Environment Interaction | 2 | 2019 | 40 | 0.540 |
Why?
| | Cell Transformation, Neoplastic | 5 | 2017 | 184 | 0.540 |
Why?
| | Research Design | 2 | 2019 | 354 | 0.540 |
Why?
| | Rats, Inbred Strains | 6 | 2015 | 187 | 0.530 |
Why?
| | Dose-Response Relationship, Drug | 10 | 2020 | 1377 | 0.530 |
Why?
| | Vehicle Emissions | 3 | 2017 | 10 | 0.520 |
Why?
| | Gene Expression Regulation | 7 | 2018 | 1006 | 0.510 |
Why?
| | Epithelial Cells | 4 | 2015 | 215 | 0.510 |
Why?
| | Halogenated Diphenyl Ethers | 2 | 2013 | 3 | 0.500 |
Why?
| | Environmental Health | 1 | 2016 | 14 | 0.500 |
Why?
| | DNA | 3 | 2016 | 550 | 0.500 |
Why?
| | Prostatic Hyperplasia | 3 | 2015 | 37 | 0.500 |
Why?
| | Endoderm | 1 | 2015 | 2 | 0.500 |
Why?
| | Diethylstilbestrol | 2 | 2008 | 12 | 0.500 |
Why?
| | Embryo Implantation | 1 | 2015 | 5 | 0.500 |
Why?
| | Diabetes, Gestational | 1 | 2016 | 52 | 0.500 |
Why?
| | Transcriptional Activation | 3 | 2013 | 128 | 0.490 |
Why?
| | Pandemics | 1 | 2020 | 585 | 0.490 |
Why?
| | Mesoderm | 1 | 2015 | 29 | 0.480 |
Why?
| | RNA, Untranslated | 1 | 2015 | 15 | 0.480 |
Why?
| | Organoids | 1 | 2015 | 39 | 0.480 |
Why?
| | Histone Code | 1 | 2015 | 32 | 0.480 |
Why?
| | Cell Differentiation | 3 | 2015 | 674 | 0.480 |
Why?
| | Estrogen Receptor alpha | 6 | 2019 | 85 | 0.470 |
Why?
| | Risk Factors | 9 | 2024 | 3872 | 0.470 |
Why?
| | Oxidative Stress | 4 | 2015 | 810 | 0.470 |
Why?
| | Maternal-Fetal Exchange | 2 | 2020 | 48 | 0.470 |
Why?
| | Urinary Bladder Neck Obstruction | 1 | 2015 | 9 | 0.470 |
Why?
| | Forkhead Transcription Factors | 2 | 2012 | 121 | 0.460 |
Why?
| | SEER Program | 1 | 2015 | 103 | 0.460 |
Why?
| | Cyclopentanes | 1 | 2014 | 12 | 0.460 |
Why?
| | Quinolines | 1 | 2014 | 44 | 0.450 |
Why?
| | Endocrinology | 1 | 2014 | 11 | 0.450 |
Why?
| | Cadmium | 2 | 2017 | 21 | 0.440 |
Why?
| | Molecular Sequence Data | 8 | 2015 | 792 | 0.440 |
Why?
| | Ovarian Neoplasms | 2 | 2010 | 459 | 0.430 |
Why?
| | Adult | 18 | 2025 | 14139 | 0.420 |
Why?
| | Nerve Tissue Proteins | 2 | 2013 | 193 | 0.420 |
Why?
| | Histone Acetyltransferases | 1 | 2013 | 25 | 0.420 |
Why?
| | Calcium-Binding Proteins | 2 | 2011 | 57 | 0.420 |
Why?
| | Toluene 2,4-Diisocyanate | 1 | 2013 | 1 | 0.420 |
Why?
| | Genomic Imprinting | 3 | 2008 | 12 | 0.410 |
Why?
| | Early Detection of Cancer | 1 | 2015 | 183 | 0.410 |
Why?
| | Androgens | 4 | 2022 | 70 | 0.410 |
Why?
| | Cell Division | 1 | 2014 | 291 | 0.410 |
Why?
| | Integrin alpha6 | 1 | 2012 | 2 | 0.410 |
Why?
| | Laminin | 1 | 2012 | 20 | 0.400 |
Why?
| | Base Sequence | 7 | 2015 | 648 | 0.400 |
Why?
| | Umbilical Cord | 1 | 2013 | 36 | 0.400 |
Why?
| | RNA, Small Interfering | 6 | 2016 | 218 | 0.400 |
Why?
| | Mitogen-Activated Protein Kinase Phosphatases | 1 | 2012 | 3 | 0.390 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2012 | 4 | 0.390 |
Why?
| | Firefighters | 1 | 2012 | 3 | 0.390 |
Why?
| | Receptors, Androgen | 4 | 2022 | 47 | 0.390 |
Why?
| | Polycyclic Compounds | 1 | 2012 | 8 | 0.390 |
Why?
| | Occupational Diseases | 1 | 2013 | 85 | 0.380 |
Why?
| | Mass Screening | 1 | 2015 | 357 | 0.380 |
Why?
| | HMGN Proteins | 1 | 2011 | 1 | 0.380 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 509 | 0.370 |
Why?
| | Histones | 6 | 2016 | 316 | 0.370 |
Why?
| | Metals, Heavy | 3 | 2018 | 11 | 0.370 |
Why?
| | Colorectal Neoplasms | 1 | 2015 | 295 | 0.360 |
Why?
| | Mothers | 2 | 2016 | 268 | 0.360 |
Why?
| | Endocrine Glands | 1 | 2011 | 5 | 0.360 |
Why?
| | Endocrine System Diseases | 1 | 2011 | 9 | 0.360 |
Why?
| | Risk | 4 | 2017 | 313 | 0.360 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2010 | 21 | 0.350 |
Why?
| | Gene Silencing | 2 | 2010 | 119 | 0.350 |
Why?
| | Hazardous Substances | 1 | 2010 | 17 | 0.350 |
Why?
| | RNA | 2 | 2012 | 172 | 0.350 |
Why?
| | Prolactin | 1 | 2010 | 43 | 0.340 |
Why?
| | Nervous System | 1 | 2010 | 32 | 0.340 |
Why?
| | Liver Neoplasms | 3 | 2024 | 332 | 0.340 |
Why?
| | RNA, Messenger | 8 | 2022 | 1142 | 0.340 |
Why?
| | Membrane Proteins | 2 | 2010 | 340 | 0.340 |
Why?
| | Genetic Vectors | 1 | 2010 | 128 | 0.340 |
Why?
| | Introns | 1 | 2010 | 54 | 0.330 |
Why?
| | Immunohistochemistry | 8 | 2016 | 985 | 0.330 |
Why?
| | Placenta | 2 | 2025 | 154 | 0.330 |
Why?
| | Mice | 15 | 2024 | 5965 | 0.320 |
Why?
| | Proteins | 3 | 2008 | 354 | 0.320 |
Why?
| | Anticarcinogenic Agents | 2 | 2006 | 32 | 0.310 |
Why?
| | Coenzyme A Ligases | 1 | 2009 | 6 | 0.310 |
Why?
| | Disease Models, Animal | 7 | 2024 | 1484 | 0.310 |
Why?
| | Testis | 2 | 2021 | 72 | 0.310 |
Why?
| | Orphan Nuclear Receptors | 2 | 2019 | 14 | 0.300 |
Why?
| | Colon | 1 | 2009 | 104 | 0.290 |
Why?
| | Antigens, Neoplasm | 1 | 2009 | 147 | 0.290 |
Why?
| | Fetus | 1 | 2009 | 194 | 0.280 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 460 | 0.280 |
Why?
| | Deoxyguanosine | 2 | 2007 | 27 | 0.280 |
Why?
| | Organ Culture Techniques | 1 | 2007 | 44 | 0.280 |
Why?
| | Cells, Cultured | 7 | 2019 | 1589 | 0.280 |
Why?
| | Ethinyl Estradiol | 2 | 2018 | 8 | 0.280 |
Why?
| | Age Factors | 4 | 2015 | 1127 | 0.270 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 163 | 0.270 |
Why?
| | Middle Aged | 15 | 2021 | 13014 | 0.270 |
Why?
| | Metabolome | 2 | 2025 | 102 | 0.270 |
Why?
| | Apigenin | 1 | 2006 | 7 | 0.270 |
Why?
| | Estrogen Receptor Modulators | 1 | 2006 | 5 | 0.270 |
Why?
| | Molecular Biology | 1 | 2007 | 27 | 0.270 |
Why?
| | Cell Line | 4 | 2016 | 1045 | 0.260 |
Why?
| | 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2006 | 6 | 0.260 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2024 | 200 | 0.260 |
Why?
| | Protein Isoforms | 4 | 2013 | 126 | 0.260 |
Why?
| | Epithelium | 3 | 2014 | 65 | 0.260 |
Why?
| | Lysine | 3 | 2015 | 92 | 0.260 |
Why?
| | Real-Time Polymerase Chain Reaction | 4 | 2014 | 186 | 0.250 |
Why?
| | Antineoplastic Agents, Hormonal | 3 | 2014 | 53 | 0.250 |
Why?
| | Proteomics | 1 | 2008 | 326 | 0.240 |
Why?
| | DNA Primers | 3 | 2012 | 209 | 0.240 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2005 | 26 | 0.240 |
Why?
| | Carcinogens | 3 | 2015 | 193 | 0.230 |
Why?
| | Polychlorinated Biphenyls | 2 | 2018 | 35 | 0.230 |
Why?
| | Animals, Newborn | 5 | 2018 | 366 | 0.230 |
Why?
| | NF-kappa B | 1 | 2006 | 328 | 0.220 |
Why?
| | DNA-Binding Proteins | 3 | 2016 | 429 | 0.220 |
Why?
| | Estrogen Antagonists | 2 | 2012 | 21 | 0.220 |
Why?
| | Reproducibility of Results | 6 | 2020 | 1214 | 0.220 |
Why?
| | Thyroid Hormones | 2 | 2016 | 22 | 0.220 |
Why?
| | Antioxidants | 1 | 2006 | 258 | 0.220 |
Why?
| | Infant, Newborn | 6 | 2025 | 2826 | 0.210 |
Why?
| | Mice, Knockout | 2 | 2024 | 909 | 0.210 |
Why?
| | beta Catenin | 1 | 2024 | 103 | 0.210 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 95 | 0.210 |
Why?
| | Stem Cells | 2 | 2015 | 182 | 0.210 |
Why?
| | Interferons | 2 | 2015 | 38 | 0.210 |
Why?
| | Kidney | 1 | 2007 | 708 | 0.200 |
Why?
| | Acetylation | 3 | 2015 | 96 | 0.200 |
Why?
| | Tumor Suppressor Proteins | 2 | 2020 | 132 | 0.200 |
Why?
| | Immediate-Early Proteins | 1 | 2002 | 18 | 0.190 |
Why?
| | Models, Biological | 5 | 2017 | 743 | 0.190 |
Why?
| | Arabidopsis Proteins | 1 | 2002 | 24 | 0.190 |
Why?
| | Pregnancy Outcome | 2 | 2017 | 250 | 0.190 |
Why?
| | Cohort Studies | 4 | 2016 | 1532 | 0.190 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2021 | 29 | 0.190 |
Why?
| | Inheritance Patterns | 1 | 2021 | 22 | 0.190 |
Why?
| | Recycling | 2 | 2018 | 3 | 0.180 |
Why?
| | Integrin alphaVbeta3 | 1 | 2021 | 4 | 0.180 |
Why?
| | Gene Expression | 3 | 2011 | 623 | 0.180 |
Why?
| | Incineration | 1 | 2021 | 5 | 0.180 |
Why?
| | Infertility, Female | 1 | 2021 | 19 | 0.180 |
Why?
| | Endometriosis | 1 | 2021 | 15 | 0.180 |
Why?
| | Endometrium | 1 | 2021 | 43 | 0.180 |
Why?
| | HEK293 Cells | 4 | 2016 | 232 | 0.180 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2021 | 58 | 0.180 |
Why?
| | Repressor Proteins | 2 | 2014 | 156 | 0.180 |
Why?
| | Loneliness | 1 | 2020 | 14 | 0.170 |
Why?
| | Hypesthesia | 1 | 2020 | 16 | 0.170 |
Why?
| | Linear Models | 2 | 2019 | 286 | 0.170 |
Why?
| | Mammary Glands, Animal | 2 | 2020 | 69 | 0.170 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2008 | 412 | 0.170 |
Why?
| | Life Style | 2 | 2019 | 145 | 0.170 |
Why?
| | Child | 4 | 2018 | 7157 | 0.170 |
Why?
| | Memory Disorders | 1 | 2020 | 48 | 0.170 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2016 | 49 | 0.170 |
Why?
| | Tissue Array Analysis | 4 | 2016 | 46 | 0.170 |
Why?
| | DNA Modification Methylases | 1 | 2020 | 28 | 0.170 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2020 | 20 | 0.170 |
Why?
| | DNA Repair Enzymes | 1 | 2020 | 43 | 0.170 |
Why?
| | Pyruvate Kinase | 1 | 2020 | 7 | 0.170 |
Why?
| | Risk Assessment | 7 | 2016 | 1323 | 0.170 |
Why?
| | Phenotype | 2 | 2015 | 799 | 0.160 |
Why?
| | Birth Weight | 3 | 2017 | 124 | 0.160 |
Why?
| | Aged | 11 | 2020 | 10109 | 0.160 |
Why?
| | Fear | 1 | 2020 | 82 | 0.160 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 99 | 0.160 |
Why?
| | Random Allocation | 2 | 2017 | 287 | 0.160 |
Why?
| | Neoplasm Staging | 3 | 2014 | 770 | 0.160 |
Why?
| | Methylation | 2 | 2020 | 126 | 0.160 |
Why?
| | Neoplasm Metastasis | 2 | 2014 | 240 | 0.160 |
Why?
| | Mice, Transgenic | 2 | 2015 | 563 | 0.160 |
Why?
| | Endometrial Neoplasms | 1 | 2020 | 144 | 0.160 |
Why?
| | Glioma | 1 | 2020 | 78 | 0.160 |
Why?
| | Blotting, Western | 3 | 2016 | 596 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2016 | 247 | 0.160 |
Why?
| | Gonadal Steroid Hormones | 2 | 2011 | 39 | 0.160 |
Why?
| | Adolescent | 4 | 2021 | 6692 | 0.160 |
Why?
| | Collagen Type III | 1 | 2019 | 7 | 0.160 |
Why?
| | Subcellular Fractions | 2 | 2012 | 34 | 0.160 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 229 | 0.150 |
Why?
| | Protein Binding | 3 | 2011 | 680 | 0.150 |
Why?
| | Urethra | 2 | 2020 | 98 | 0.150 |
Why?
| | Models, Genetic | 2 | 2011 | 172 | 0.150 |
Why?
| | Liver Failure, Acute | 1 | 2019 | 56 | 0.150 |
Why?
| | Binding Sites | 3 | 2022 | 379 | 0.150 |
Why?
| | Young Adult | 6 | 2025 | 4319 | 0.150 |
Why?
| | Methylmercury Compounds | 1 | 2018 | 5 | 0.150 |
Why?
| | Collagen Type I | 1 | 2019 | 83 | 0.150 |
Why?
| | Denmark | 1 | 2018 | 23 | 0.150 |
Why?
| | Reactive Oxygen Species | 2 | 2015 | 425 | 0.150 |
Why?
| | Age Distribution | 2 | 2015 | 174 | 0.150 |
Why?
| | Hair | 1 | 2018 | 29 | 0.150 |
Why?
| | Computational Biology | 2 | 2017 | 211 | 0.140 |
Why?
| | Incidence | 3 | 2017 | 1059 | 0.140 |
Why?
| | Prognosis | 4 | 2017 | 2094 | 0.140 |
Why?
| | T-Lymphocytes | 2 | 2017 | 340 | 0.140 |
Why?
| | Water Pollutants, Chemical | 1 | 2018 | 54 | 0.140 |
Why?
| | Survival Analysis | 2 | 2016 | 671 | 0.140 |
Why?
| | Urethane | 1 | 2017 | 5 | 0.140 |
Why?
| | Histone Demethylases | 1 | 2017 | 19 | 0.140 |
Why?
| | Antigens, CD1 | 1 | 2017 | 9 | 0.140 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 2 | 2008 | 10 | 0.140 |
Why?
| | Antigen Presentation | 1 | 2017 | 26 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 224 | 0.140 |
Why?
| | Tumor Cells, Cultured | 2 | 2014 | 456 | 0.130 |
Why?
| | Fibroblasts | 1 | 2019 | 359 | 0.130 |
Why?
| | Cholesterol | 1 | 2017 | 156 | 0.130 |
Why?
| | Gonads | 1 | 2016 | 6 | 0.130 |
Why?
| | 5-Methylcytosine | 1 | 2016 | 16 | 0.130 |
Why?
| | Brain Neoplasms | 1 | 2020 | 290 | 0.130 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2014 | 222 | 0.130 |
Why?
| | Hippocampus | 1 | 2018 | 201 | 0.130 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 14 | 0.130 |
Why?
| | Soil Pollutants | 1 | 2016 | 12 | 0.130 |
Why?
| | Methyltransferases | 1 | 2016 | 29 | 0.130 |
Why?
| | Genetic Loci | 1 | 2016 | 49 | 0.130 |
Why?
| | Dust | 1 | 2016 | 23 | 0.130 |
Why?
| | Soil | 1 | 2016 | 26 | 0.130 |
Why?
| | Fetal Development | 1 | 2016 | 50 | 0.130 |
Why?
| | Exercise | 1 | 2020 | 548 | 0.130 |
Why?
| | Heart Diseases | 1 | 2019 | 222 | 0.130 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2016 | 56 | 0.130 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2015 | 4 | 0.120 |
Why?
| | Genital Neoplasms, Male | 1 | 2015 | 2 | 0.120 |
Why?
| | Myocardium | 1 | 2019 | 480 | 0.120 |
Why?
| | Immunologic Surveillance | 1 | 2015 | 10 | 0.120 |
Why?
| | Advanced Oxidation Protein Products | 1 | 2015 | 1 | 0.120 |
Why?
| | Logistic Models | 1 | 2018 | 920 | 0.120 |
Why?
| | Regression Analysis | 2 | 2015 | 401 | 0.120 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 97 | 0.120 |
Why?
| | Exosomes | 1 | 2016 | 56 | 0.120 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 2015 | 50 | 0.120 |
Why?
| | Cell Survival | 2 | 2008 | 602 | 0.120 |
Why?
| | Spectrometry, Fluorescence | 1 | 2015 | 46 | 0.120 |
Why?
| | Environment | 1 | 2016 | 88 | 0.120 |
Why?
| | Myeloid Cells | 1 | 2015 | 39 | 0.120 |
Why?
| | Prostatectomy | 1 | 2016 | 84 | 0.120 |
Why?
| | Isoenzymes | 2 | 2006 | 167 | 0.120 |
Why?
| | Mammaglobin B | 1 | 2015 | 1 | 0.120 |
Why?
| | Weaning | 1 | 2015 | 30 | 0.120 |
Why?
| | Genital Neoplasms, Female | 1 | 2015 | 48 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2015 | 232 | 0.120 |
Why?
| | Urinary Bladder | 1 | 2015 | 101 | 0.120 |
Why?
| | Hyperplasia | 1 | 2015 | 98 | 0.110 |
Why?
| | Lung Neoplasms | 2 | 2020 | 636 | 0.110 |
Why?
| | Precancerous Conditions | 2 | 2006 | 85 | 0.110 |
Why?
| | Schools | 1 | 2016 | 172 | 0.110 |
Why?
| | Up-Regulation | 4 | 2019 | 462 | 0.110 |
Why?
| | Gestational Age | 1 | 2016 | 412 | 0.110 |
Why?
| | Inflammasomes | 1 | 2015 | 66 | 0.110 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2014 | 48 | 0.110 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 79 | 0.110 |
Why?
| | Immunoenzyme Techniques | 1 | 2014 | 137 | 0.110 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 879 | 0.110 |
Why?
| | Erectile Dysfunction | 1 | 2015 | 93 | 0.110 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2014 | 21 | 0.110 |
Why?
| | Alleles | 1 | 2015 | 277 | 0.110 |
Why?
| | History, 21st Century | 1 | 2014 | 59 | 0.110 |
Why?
| | Protein Processing, Post-Translational | 2 | 2012 | 158 | 0.110 |
Why?
| | History, 20th Century | 1 | 2014 | 96 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 484 | 0.110 |
Why?
| | Gene Deletion | 1 | 2015 | 276 | 0.110 |
Why?
| | Age of Onset | 1 | 2014 | 109 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 334 | 0.110 |
Why?
| | Tamoxifen | 2 | 2012 | 60 | 0.100 |
Why?
| | Methacholine Chloride | 1 | 2013 | 3 | 0.100 |
Why?
| | Nitrates | 1 | 2013 | 31 | 0.100 |
Why?
| | Sp1 Transcription Factor | 2 | 2024 | 20 | 0.100 |
Why?
| | Ohio | 1 | 2013 | 45 | 0.100 |
Why?
| | Hydroxylation | 1 | 2013 | 64 | 0.100 |
Why?
| | China | 3 | 2018 | 134 | 0.100 |
Why?
| | Exons | 1 | 2013 | 102 | 0.100 |
Why?
| | MAP Kinase Kinase Kinase 1 | 1 | 2012 | 4 | 0.100 |
Why?
| | Metabolomics | 2 | 2025 | 151 | 0.100 |
Why?
| | Flow Cytometry | 2 | 2014 | 404 | 0.100 |
Why?
| | Confidence Intervals | 1 | 2013 | 158 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2019 | 1903 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 129 | 0.100 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2012 | 63 | 0.100 |
Why?
| | Oncogene Proteins | 1 | 2012 | 19 | 0.100 |
Why?
| | Saliva | 1 | 2012 | 56 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2016 | 2268 | 0.100 |
Why?
| | Eyelids | 1 | 2012 | 29 | 0.100 |
Why?
| | Ovary | 2 | 2020 | 107 | 0.100 |
Why?
| | Smoke | 1 | 2012 | 18 | 0.100 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2012 | 36 | 0.100 |
Why?
| | In Situ Hybridization | 2 | 2010 | 69 | 0.100 |
Why?
| | Cell Adhesion | 1 | 2012 | 164 | 0.100 |
Why?
| | Mice, Nude | 4 | 2014 | 236 | 0.100 |
Why?
| | Leukocyte Count | 1 | 2012 | 73 | 0.100 |
Why?
| | Child, Preschool | 2 | 2012 | 4030 | 0.100 |
Why?
| | RNA Splicing | 1 | 2012 | 41 | 0.090 |
Why?
| | Antibodies | 2 | 2012 | 152 | 0.090 |
Why?
| | Phytoestrogens | 2 | 2014 | 23 | 0.090 |
Why?
| | Azacitidine | 1 | 2011 | 39 | 0.090 |
Why?
| | Phosphorylation | 3 | 2020 | 531 | 0.090 |
Why?
| | Carrier Proteins | 1 | 2013 | 326 | 0.090 |
Why?
| | Adult Stem Cells | 1 | 2011 | 11 | 0.090 |
Why?
| | Peptide Hormones | 1 | 2011 | 4 | 0.090 |
Why?
| | Cell Cycle | 2 | 2012 | 240 | 0.090 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2011 | 37 | 0.090 |
Why?
| | Calcitriol | 1 | 2011 | 39 | 0.090 |
Why?
| | Biomedical Research | 1 | 2014 | 256 | 0.090 |
Why?
| | Tubulin Modulators | 1 | 2011 | 28 | 0.090 |
Why?
| | Nitric Oxide | 1 | 2012 | 244 | 0.090 |
Why?
| | Calgranulin B | 1 | 2010 | 4 | 0.090 |
Why?
| | Bromocriptine | 1 | 2010 | 5 | 0.090 |
Why?
| | Environmental Pollution | 1 | 2010 | 14 | 0.090 |
Why?
| | Chemokine CXCL13 | 1 | 2010 | 6 | 0.090 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 84 | 0.090 |
Why?
| | Tretinoin | 1 | 2011 | 54 | 0.090 |
Why?
| | Cell Nucleus | 2 | 2016 | 191 | 0.090 |
Why?
| | Paclitaxel | 1 | 2011 | 90 | 0.090 |
Why?
| | Muscle Proteins | 1 | 2013 | 347 | 0.090 |
Why?
| | Feedback, Physiological | 1 | 2010 | 12 | 0.090 |
Why?
| | United States | 4 | 2015 | 5182 | 0.090 |
Why?
| | Genes, abl | 1 | 2010 | 2 | 0.080 |
Why?
| | Staining and Labeling | 2 | 2016 | 92 | 0.080 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2010 | 74 | 0.080 |
Why?
| | Autoimmunity | 1 | 2010 | 34 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 149 | 0.080 |
Why?
| | Interleukin-1beta | 1 | 2010 | 86 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2011 | 134 | 0.080 |
Why?
| | Disease-Free Survival | 1 | 2010 | 460 | 0.080 |
Why?
| | New York City | 1 | 2009 | 25 | 0.080 |
Why?
| | Adenoma, Villous | 1 | 2009 | 1 | 0.080 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 443 | 0.080 |
Why?
| | Ecotoxicology | 1 | 2008 | 4 | 0.080 |
Why?
| | Administration, Oral | 2 | 2010 | 451 | 0.080 |
Why?
| | Sequence Deletion | 1 | 2009 | 73 | 0.080 |
Why?
| | Genital Diseases, Female | 1 | 2008 | 17 | 0.080 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 28 | 0.070 |
Why?
| | Biopsy | 2 | 2021 | 604 | 0.070 |
Why?
| | Public Health Practice | 1 | 2008 | 42 | 0.070 |
Why?
| | ROC Curve | 1 | 2009 | 251 | 0.070 |
Why?
| | Behavior, Animal | 2 | 2020 | 187 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 185 | 0.070 |
Why?
| | Apoptosis | 1 | 2013 | 1127 | 0.070 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 2007 | 11 | 0.070 |
Why?
| | Microdissection | 1 | 2007 | 20 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2010 | 327 | 0.070 |
Why?
| | Lasers | 1 | 2007 | 65 | 0.070 |
Why?
| | Nitric Oxide Synthase | 1 | 2007 | 64 | 0.070 |
Why?
| | Cyclooxygenase 2 | 1 | 2007 | 50 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2015 | 1201 | 0.070 |
Why?
| | Presenilin-2 | 1 | 2006 | 2 | 0.070 |
Why?
| | Yeasts | 1 | 2006 | 9 | 0.070 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 19 | 0.070 |
Why?
| | Dimerization | 1 | 2006 | 51 | 0.070 |
Why?
| | Proteome | 1 | 2008 | 170 | 0.070 |
Why?
| | Caspase 3 | 1 | 2006 | 94 | 0.070 |
Why?
| | Growth Differentiation Factor 1 | 1 | 2006 | 2 | 0.060 |
Why?
| | Consensus | 1 | 2007 | 180 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 397 | 0.060 |
Why?
| | Oxidation-Reduction | 1 | 2007 | 328 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2016 | 6578 | 0.060 |
Why?
| | Protein Biosynthesis | 2 | 2013 | 265 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2006 | 272 | 0.060 |
Why?
| | Spinacia oleracea | 1 | 2006 | 7 | 0.060 |
Why?
| | Interleukin-12 | 1 | 2006 | 27 | 0.060 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2006 | 52 | 0.060 |
Why?
| | Interleukin-8 | 1 | 2006 | 86 | 0.060 |
Why?
| | Phytotherapy | 1 | 2006 | 45 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2006 | 106 | 0.060 |
Why?
| | Organ Size | 2 | 2016 | 231 | 0.060 |
Why?
| | Phthalic Acids | 1 | 2025 | 6 | 0.060 |
Why?
| | Models, Molecular | 1 | 2006 | 352 | 0.060 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 591 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 1222 | 0.060 |
Why?
| | MCF-7 Cells | 2 | 2016 | 62 | 0.060 |
Why?
| | Oxygen Consumption | 1 | 2006 | 198 | 0.060 |
Why?
| | Alternative Splicing | 1 | 2005 | 62 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2025 | 122 | 0.060 |
Why?
| | Down-Regulation | 2 | 2021 | 347 | 0.060 |
Why?
| | TATA Box | 1 | 2004 | 8 | 0.060 |
Why?
| | Dinucleoside Phosphates | 1 | 2004 | 7 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2017 | 338 | 0.060 |
Why?
| | Transfection | 1 | 2005 | 372 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 2 | 2017 | 250 | 0.060 |
Why?
| | Infant | 1 | 2012 | 3684 | 0.060 |
Why?
| | Orchiectomy | 1 | 2003 | 38 | 0.050 |
Why?
| | Oxidoreductases | 1 | 2003 | 59 | 0.050 |
Why?
| | Androgen-Binding Protein | 1 | 2003 | 1 | 0.050 |
Why?
| | Prostatic Secretory Proteins | 1 | 2003 | 1 | 0.050 |
Why?
| | Seminal Vesicle Secretory Proteins | 1 | 2003 | 1 | 0.050 |
Why?
| | Colitis, Ulcerative | 1 | 2024 | 67 | 0.050 |
Why?
| | Aldehydes | 1 | 2003 | 81 | 0.050 |
Why?
| | Peptide Elongation Factor 1 | 1 | 2003 | 2 | 0.050 |
Why?
| | Plant Extracts | 1 | 2006 | 193 | 0.050 |
Why?
| | Clusterin | 1 | 2003 | 8 | 0.050 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2003 | 6 | 0.050 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2003 | 6 | 0.050 |
Why?
| | Glutathione Reductase | 1 | 2003 | 14 | 0.050 |
Why?
| | Postoperative Period | 1 | 2003 | 170 | 0.050 |
Why?
| | Glutathione Peroxidase | 1 | 2003 | 23 | 0.050 |
Why?
| | Cytoskeleton | 1 | 2003 | 39 | 0.050 |
Why?
| | Malondialdehyde | 1 | 2003 | 54 | 0.050 |
Why?
| | Regeneration | 1 | 2003 | 79 | 0.050 |
Why?
| | Catalase | 1 | 2003 | 74 | 0.050 |
Why?
| | Lipid Peroxidation | 1 | 2003 | 97 | 0.050 |
Why?
| | Alkaline Phosphatase | 1 | 2003 | 94 | 0.050 |
Why?
| | Molecular Chaperones | 1 | 2003 | 78 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2003 | 120 | 0.050 |
Why?
| | Glycoproteins | 1 | 2003 | 123 | 0.050 |
Why?
| | Receptors, Vasoactive Intestinal Polypeptide, Type I | 1 | 2002 | 1 | 0.050 |
Why?
| | Receptors, Vasoactive Intestinal Peptide | 1 | 2002 | 3 | 0.050 |
Why?
| | Radioimmunoassay | 1 | 2002 | 41 | 0.050 |
Why?
| | Peer Review | 1 | 2002 | 9 | 0.050 |
Why?
| | Endocrine System | 1 | 2002 | 16 | 0.050 |
Why?
| | Early Growth Response Protein 1 | 1 | 2002 | 34 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2014 | 278 | 0.050 |
Why?
| | Sp3 Transcription Factor | 1 | 2022 | 5 | 0.050 |
Why?
| | RNA Polymerase II | 1 | 2022 | 14 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2002 | 88 | 0.050 |
Why?
| | Adenosine Triphosphatases | 1 | 2002 | 91 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2003 | 244 | 0.050 |
Why?
| | Plant Proteins | 1 | 2002 | 70 | 0.050 |
Why?
| | Mutation | 1 | 2007 | 1351 | 0.050 |
Why?
| | Mitochondria | 1 | 2005 | 428 | 0.050 |
Why?
| | Amino Acids | 1 | 2023 | 377 | 0.050 |
Why?
| | Principal Component Analysis | 1 | 2021 | 53 | 0.050 |
Why?
| | Trans-Activators | 1 | 2002 | 138 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2015 | 3391 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 44 | 0.040 |
Why?
| | Alcohol Oxidoreductases | 1 | 2020 | 13 | 0.040 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2020 | 4 | 0.040 |
Why?
| | Thyroid Gland | 1 | 2020 | 79 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2020 | 146 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2019 | 40 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2019 | 103 | 0.040 |
Why?
| | Transcription Factors | 1 | 2002 | 574 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2019 | 194 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 1676 | 0.040 |
Why?
| | Fibrosis | 1 | 2019 | 197 | 0.040 |
Why?
| | Prospective Studies | 2 | 2015 | 2428 | 0.040 |
Why?
| | Apgar Score | 1 | 2017 | 35 | 0.040 |
Why?
| | Pilot Projects | 1 | 2020 | 719 | 0.040 |
Why?
| | United States Environmental Protection Agency | 2 | 2007 | 8 | 0.040 |
Why?
| | Diet, Atherogenic | 1 | 2017 | 10 | 0.030 |
Why?
| | Heart | 1 | 2020 | 357 | 0.030 |
Why?
| | Gasoline | 1 | 2017 | 2 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2017 | 40 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 2017 | 57 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 2 | 2007 | 42 | 0.030 |
Why?
| | Endosomes | 1 | 2017 | 36 | 0.030 |
Why?
| | Endocytosis | 1 | 2017 | 55 | 0.030 |
Why?
| | Time Factors | 2 | 2014 | 2957 | 0.030 |
Why?
| | Thyroid Function Tests | 1 | 2016 | 27 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 727 | 0.030 |
Why?
| | Acetaminophen | 1 | 2019 | 279 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 179 | 0.030 |
Why?
| | Lung | 1 | 2020 | 502 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2017 | 188 | 0.030 |
Why?
| | Hormone Replacement Therapy | 1 | 2015 | 21 | 0.030 |
Why?
| | Drug Implants | 1 | 2015 | 35 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 230 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 126 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2016 | 182 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 150 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2015 | 172 | 0.030 |
Why?
| | Sp Transcription Factors | 1 | 2014 | 6 | 0.030 |
Why?
| | Pentacyclic Triterpenes | 1 | 2014 | 8 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2015 | 66 | 0.030 |
Why?
| | Triterpenes | 1 | 2014 | 11 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 87 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 79 | 0.030 |
Why?
| | HMGA Proteins | 1 | 2014 | 2 | 0.030 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2014 | 71 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2015 | 117 | 0.030 |
Why?
| | Caspase 7 | 1 | 2013 | 7 | 0.030 |
Why?
| | Genome | 1 | 2014 | 62 | 0.030 |
Why?
| | 5' Untranslated Regions | 1 | 2013 | 30 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2013 | 55 | 0.030 |
Why?
| | Weight Gain | 1 | 2015 | 240 | 0.030 |
Why?
| | Transcription Factor AP-2 | 1 | 2012 | 3 | 0.030 |
Why?
| | Laser Capture Microdissection | 1 | 2012 | 6 | 0.030 |
Why?
| | Receptors, Steroid | 1 | 2012 | 20 | 0.020 |
Why?
| | Progesterone | 1 | 2012 | 58 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2012 | 137 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2012 | 174 | 0.020 |
Why?
| | Serum Response Factor | 1 | 2012 | 45 | 0.020 |
Why?
| | Blood Glucose | 1 | 2015 | 471 | 0.020 |
Why?
| | Doxorubicin | 1 | 2013 | 239 | 0.020 |
Why?
| | Cell Death | 1 | 2012 | 176 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 83 | 0.020 |
Why?
| | Cisplatin | 1 | 2013 | 285 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 95 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 643 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2012 | 127 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 569 | 0.020 |
Why?
| | Albumins | 1 | 2011 | 32 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2011 | 74 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2011 | 69 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2010 | 50 | 0.020 |
Why?
| | STAT1 Transcription Factor | 1 | 2010 | 27 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2011 | 312 | 0.020 |
Why?
| | Carcinoma, Lobular | 1 | 2010 | 32 | 0.020 |
Why?
| | Receptors, Progesterone | 1 | 2010 | 66 | 0.020 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2010 | 46 | 0.020 |
Why?
| | Nanoparticles | 1 | 2011 | 127 | 0.020 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2010 | 89 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2011 | 146 | 0.020 |
Why?
| | Dihydrotestosterone | 1 | 2007 | 14 | 0.020 |
Why?
| | Animals, Wild | 1 | 2007 | 10 | 0.020 |
Why?
| | North Carolina | 1 | 2007 | 56 | 0.020 |
Why?
| | Models, Animal | 1 | 2007 | 228 | 0.020 |
Why?
| | Public Health | 1 | 2002 | 221 | 0.010 |
Why?
|
|
Ho's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|